Holen Sie sich die Stockscreener-App
71.88
0.18%
-0.13
Handel nachbörslich:
71.88
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
Corcept Therapeutics’ Korlym Shows Glucose Control, Weight Reduction in Hypercortisolism, Type 2 Diabetes Patients - MSN
Corcept Therapeutics: A New Standard of Care in Ovarian Cancer Emerges - AInvest
Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial - MSN
Corcept therapeutics officer Guyer sells $7350 in shares By Investing.com - Investing.com South Africa
Corcept therapeutics officer Guyer sells $7350 in shares - Investing.com
Corcept Therapeutics: A Breakthrough in Rare Diseases and Beyond - AInvest
Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 2000 Growth Index - MarketScreener
Major Diabetes Discovery: Hidden Hormone Problem Found in 1 in 4 Treatment-Resistant Patients, New Study Shows - Stock Titan
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much TodayCorcept Therapeutics (NASDAQ:CORT) - Benzinga
Corcept reports annual meeting outcomes By Investing.com - Investing.com Canada
Corcept May 2025 slides: Revenue target of $900-950M amid pipeline advances - Investing.com Canada
Corcept Therapeutics director Daniel Swisher sells $155k in stock By Investing.com - Investing.com Nigeria
Corcept Therapeutics director Daniel Swisher sells $155k in stock - Investing.com Australia
Insider Sell: Swisher Daniel N JR Sells 2,200 Shares of Corcept Therapeutics Inc (CORT) - GuruFocus
Relacorilant delays ovarian cancer disease progression: Trial data - Rare Cancer News
Corcept claims survival benefit in ALS despite missed endpoint - PharmaLive
Mixed Phase II results for Corcept’s dazucorilant - The Pharma Letter
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Purchased by Public Employees Retirement System of Ohio - Defense World
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting - afp.com
Corcept plots future for ALS drug that flunked Phase 2, citing survival analysis - Endpoints News
Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study - Benzinga
Corcept's mid-stage ALS study fails (CORT:NASDAQ) - Seeking Alpha
Corcept Presents Results from Phase 2 Study of Dazucorilant in P - GuruFocus
Corcept Therapeutics Says Its ALS Drug Candidate Fails to Meet Primary Goal - marketscreener.com
Corcept Therapeutics (CORT) Reports Promising Survival Data in A - GuruFocus
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting | CORT Stock News - GuruFocus
Corcept Therapeutics (CORT) Reports Promising Survival Data in ALS Study | CORT Stock News - GuruFocus
Corcept therapeutics officer Joseph Lyon sells shares worth $390,218 By Investing.com - Investing.com Canada
Corcept therapeutics officer Joseph Lyon sells shares worth $390,218 - Investing.com Australia
Corcept (CORT) Down 1.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
H.C. Wainwright Reaffirms Corcept Therapeutics Incorporated (CORT)’s $145 Price Target, Maintains Buy Rating - Insider Monkey
ASCO 2025: Corcept Therapeutics’ relacorilant emerges as promising agent in recurrent ovarian cancer - Yahoo Finance
Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday - Yahoo
Corcept Therapeutics (NasdaqCM:CORT) Announces Positive Phase 3 Results For Ovarian Cancer Treatment - Yahoo Finance
Relacorilant shows promise for ovarian cancer treatment By Investing.com - Investing.com Nigeria
Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with - GuruFocus
Corcept Therapeutics (CORT) Shows Positive Phase 3 Trial Results for Ovarian Cancer Treatment | CORT Stock News - GuruFocus
Corcept shares rise on positive Phase 3 trial results By Investing.com - Investing.com Nigeria
Corcept shares rise on positive Phase 3 trial results - Investing.com Australia
Relacorilant shows promise for ovarian cancer treatment - Investing.com
Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer - Business Wire
Zacks Research Issues Pessimistic Outlook for CORT Earnings - Defense World
Here's How Much $1000 Invested In Corcept Therapeutics 5 Years Ago Would Be Worth Today - Benzinga
Zacks Research Has Negative Outlook for CORT Q2 Earnings - Defense World
Equities Analysts Offer Predictions for CORT Q1 Earnings - Defense World
Bank of America Corp DE Cuts Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Nuveen Asset Management LLC - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock Holdings Lessened by Cetera Investment Advisers - Defense World
Abortion Drugs Market Deep Research and Growth in Future Scope - openPR.com
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT) - FinancialContent
Director, Oncology Patient Support OperationsRedwood CityCorcept Therapeutics - Ladders
Deutsche Bank AG Buys 24,051 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Navigating Insider Activity at Corcept Therapeutics: Is the Sell-Side Missing the Bigger Picture? - AInvest
CORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance Reaffirmed - Yahoo Finance
2.10%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):